BASEL, Switzerland, May 10, 2023 VectivBio Holding AG , a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the. | May 10, 2023
Continued Strong Progress and Momentum Across Multiple Programs with Key Upcoming Data Milestones Beginning Q2 2023 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal. | April 19, 2023
Management to Host Conference Call Wednesday, April 19, 2023, at 8.00 a.m. ETBASEL, Switzerland, April 12, 2023 VectivBio Holding AG , a clinical-stage biopharmaceutical company pioneering. | April 12, 2023
Resignation of Director On December 27, 2022, Chahra Louafi submitted her resignation from the Board of Directors of VectivBio Holding AG , which resignation was. | December 30, 2022